89164-77-2 Usage
Type
Semi-synthetic anthracycline antibiotic
Purpose
Anticancer activity
Derivative of
Doxorubicin
Designed to
Overcome limitations and side effects of doxorubicin
Effective against
Breast, lung, and colon cancer
Potential for
Cancers resistant to doxorubicin treatment
Mechanism
Inhibits growth of cancer cells, better tissue penetration, enhanced DNA binding
Clinical trials
Ongoing for safety and efficacy
Hope
Valuable addition to existing anticancer drugs
Check Digit Verification of cas no
The CAS Registry Mumber 89164-77-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,1,6 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 89164-77:
(7*8)+(6*9)+(5*1)+(4*6)+(3*4)+(2*7)+(1*7)=172
172 % 10 = 2
So 89164-77-2 is a valid CAS Registry Number.
InChI:InChI=1/C32H36N2O12/c1-14-27(37)18(34-6-7-44-13-15(34)11-33)8-22(45-14)46-20-10-32(42,21(36)12-35)9-17-24(20)31(41)26-25(29(17)39)28(38)16-4-3-5-19(43-2)23(16)30(26)40/h3-5,14-15,18,20-22,27,35-37,39,41-42H,6-10,12-13H2,1-2H3
89164-77-2Relevant articles and documents
Intensely potent morpholinyl anthracyclines
Acton,Tong,Mosher,Wolgemuth
, p. 638 - 645 (2007/10/02)
3'-Deamino-3'-(3-cyano-4-morpholinyl)doxorubicin is a new analogue that is 100 to 1000 times more potent than doxorubicin against tumors in cell culture or in mice, that is active by intraperitoneal, intravenous, or oral dosing, and that does not produce chronic myocardial lesions in mice. This analogue was encountered in studies on the reductive alkylation of doxorubicin and daunorubicin with 2,2'-oxybis[acetaldehyde], which constructs a morpholino ring incorporating the amino N. The morpholinyl nitrile byproducts are separated by virtue of their nonbasicity from the expected morpholino derivatives. The 13-dihydro and 5-imino derivatives are also described in this important new class of anthracyclines.
